Medical Research Finder

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

VE303

Navigation

Contents

VE303 is a defined bacterial consortium that originates from human stools and is produced from clonal cell banks.
Benech et al. 2024 Clinical Microbiology and Infection 30: 462-468

It consists of 8 well-characterized Clostridioides strains (including 5 strains from Clostridia cluster XIVa, 2 strains from cluster IV, and 1 strain from cluster XVII) that are considered commensal and do not produce toxins and is developed by Vedanta Biosciences
Louie et al. 2023 JAMA 329: 1356
Dsouza et al. 2022 Cell & Host Microbe 30: 583–598
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656

see also:
Microbiome-based therapeutics
Next-Generation Probiotics (NGPs)

References (Sources)

Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Dsouza et al. 2022 Cell & Host Microbe 30: 583–598
First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech et al. 2024 Clinical Microbiology and Infection 30: 462-468
Review
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection A Randomized Clinical Trial
Louie et al. 2023 JAMA 329: 1356

AI Chat

5/29/2026

Chat with our artificial intelligence: